Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Terminated Phase 4 Interventional Results available

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346
View directory record Official record
Conditions
Epilepsy
Interventions
ezogabine/retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Bethesda, Maryland • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 23, 2026, 9:00 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Neurogenetic Disorders

NCT03492060
View directory record Official record
Conditions
Neurodevelopmental Disorders, Intellectual Disability, Developmental Delay, Autism Spectrum Disorder, Seizures, Hypertonia, Muscle, Hypotonia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 23, 2026, 9:00 PM EDT
Completed No phase listed Observational

Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC

NCT01767779
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 6 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 23, 2026, 9:00 PM EDT
Not listed No phase listed Observational

microEEG for Neonatal Apnea, Bradycardia and Desaturation

NCT02436616
View directory record Official record
Conditions
Apnea, Bradycardia, Premature Birth, Seizures
Interventions
microEEG
Device
Lead sponsor
Bio-Signal Group Corp.
Industry
Eligibility
Up to 30 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 23, 2026, 9:00 PM EDT
Completed No phase listed Observational

Human Epilepsy Project 2: Resistant Focal Seizures Study

NCT03531008
View directory record Official record
Conditions
Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
Interventions
Not listed
Lead sponsor
Epilepsy Foundation of America
Other
Eligibility
16 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 23, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

NCT01002820
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Lexington, Kentucky • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 23, 2026, 9:00 PM EDT
Completed Phase 4 Interventional Results available

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

NCT01318408
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
60 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 23, 2026, 9:00 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial

NCT00293735
View directory record Official record
Conditions
Preeclampsia, Pregnancy Induced Hypertension, Gestational Hypertension, Chronic Hypertension, Superimposed Preeclampsia
Interventions
labetalol (seizure prevention), MgSO4 (seizure prevention)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
15 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 23, 2026, 9:00 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243
View directory record Official record
Conditions
Epilepsies, Myoclonic
Interventions
Placebo, Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 23, 2026, 9:00 PM EDT
Active, not recruiting No phase listed Observational

A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

NCT07723950
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
No intervention
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 9:00 PM EDT
Recruiting Phase 2 Interventional

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

NCT05518578
View directory record Official record
Conditions
Epilepsy, Seizures, Epileptic
Interventions
SPN-817
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blast Exposed Veterans With Auditory Complaints

NCT02122458
View directory record Official record
Conditions
Hearing Impairment, Hearing Aid Fitting
Interventions
mild-gain hearing aids with high-frequency emphasis over 6-months
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 50 Years
Enrollment
363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
3
States / cities
Portland, Oregon • Pittsburgh, Pennsylvania • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 9:00 PM EDT
Completed No phase listed Observational

Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy

NCT01214707
View directory record Official record
Conditions
Epilepsy
Interventions
Exercise
Other
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 23, 2026, 9:00 PM EDT
Completed No phase listed Observational Results available

Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation

NCT02385526
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Vagus Nerve Stimulation Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 23, 2026, 9:00 PM EDT
Recruiting Early Phase 1 Interventional

Accelerated TMS for Seizure-Type Functional Neurologic Disorders

NCT07059325
View directory record Official record
Conditions
Functional Neurological Symptom Disorder, Functional Seizures
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 9:00 PM EDT
Completed No phase listed Observational

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

NCT04259125
View directory record Official record
Conditions
Neonatal Seizure, Epilepsy, Seizures, Inflammatory Response
Interventions
Blood draw, Survey
Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 4 Days
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 9:00 PM EDT
Terminated No phase listed Observational

The Role of Serotonin in Seizures

NCT00439387
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 23, 2026, 9:00 PM EDT
Terminated Not applicable Interventional Results available

Lacosamide in Preventing Seizures in Participants With Malignant Glioma

NCT01432171
View directory record Official record
Conditions
Malignant Glioma
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 23, 2026, 9:00 PM EDT
Not yet recruiting Not applicable Interventional

Epileptiform Potential of Fully Immersive Virtual Reality

NCT07451093
View directory record Official record
Conditions
Epilepsy, Seizure
Interventions
Virtual Reality Headset, display off, Virtual Reality Headset, Display only, Virtual Reality Headset, Display and Hand Control
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 23, 2026, 9:00 PM EDT
Completed No phase listed Observational

Earbud EEG Feasibility Study

NCT05257811
View directory record Official record
Conditions
Epilepsy; Seizure, Sleep
Interventions
NextSense EEG-enabled earbuds
Device
Lead sponsor
NextSense, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 23, 2026, 9:00 PM EDT
Terminated No phase listed Observational

Observational Study of Males With Creatine Transporter Deficiency

NCT02931682
View directory record Official record
Conditions
Creatine Deficiency, X-linked
Interventions
Not listed
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
6 Months to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

RNS® System Pivotal Study

NCT00264810
View directory record Official record
Conditions
Epilepsy
Interventions
RNS® System implantation, RNS® System responsive stimulation
Procedure · Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy

NCT03428360
View directory record Official record
Conditions
Epilepsy
Interventions
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
2 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Honolulu, Hawaii • Boise, Idaho • Voorhees Township, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 23, 2026, 9:00 PM EDT